Garbe C - Search Results

1

BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.

Niessner H, Sinnberg T, Kosnopfel C, Smalley KSM, Beck D, Praetorius C, Mai M, Beissert S, Kulms D, Schaller M, Garbe C, Flaherty KT, Westphal D, Wanke I, Meier F. Niessner H, et al. Among authors: garbe c. Clin Cancer Res. 2017 Oct 15;23(20):6203-6214. doi: 10.1158/1078-0432.CCR-17-0098. Epub 2017 Jul 19. Clin Cancer Res. 2017. PMID: 28724666 Free PMC article.

2

Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy.

Garbe C, Paul A, Kohler-Späth H, Ellwanger U, Stroebel W, Schwarz M, Schlagenhauff B, Meier F, Schittek B, Blaheta HJ, Blum A, Rassner G. Garbe C, et al. J Clin Oncol. 2003 Feb 1;21(3):520-9. doi: 10.1200/JCO.2003.01.091. J Clin Oncol. 2003. PMID: 12560444

3

Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.

Garbe C, Leiter U, Ellwanger U, Blaheta HJ, Meier F, Rassner G, Schittek B. Garbe C, et al. Cancer. 2003 Apr 1;97(7):1737-45. doi: 10.1002/cncr.11250. Cancer. 2003. PMID: 12655531 Free article.

4

Fibroblast growth factor-2 but not Mel-CAM and/or beta3 integrin promotes progression of melanocytes to melanoma.

Meier F, Caroli U, Satyamoorthy K, Schittek B, Bauer J, Berking C, Möller H, Maczey E, Rassner G, Herlyn M, Garbe C. Meier F, et al. Among authors: garbe c. Exp Dermatol. 2003 Jun;12(3):296-306. doi: 10.1034/j.1600-0625.2003.120310.x. Exp Dermatol. 2003. PMID: 12823444

5

The natural course of cutaneous melanoma.

Leiter U, Meier F, Schittek B, Garbe C. Leiter U, et al. Among authors: garbe c. J Surg Oncol. 2004 Jul 1;86(4):172-8. doi: 10.1002/jso.20079. J Surg Oncol. 2004. PMID: 15221923 Review.

6

The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma.

Meier F, Schittek B, Busch S, Garbe C, Smalley K, Satyamoorthy K, Li G, Herlyn M. Meier F, et al. Among authors: garbe c. Front Biosci. 2005 Sep 1;10:2986-3001. doi: 10.2741/1755. Front Biosci. 2005. PMID: 15970553 Review.

7

The adhesion molecule L1 (CD171) promotes melanoma progression.

Meier F, Busch S, Gast D, Göppert A, Altevogt P, Maczey E, Riedle S, Garbe C, Schittek B. Meier F, et al. Among authors: garbe c. Int J Cancer. 2006 Aug 1;119(3):549-55. doi: 10.1002/ijc.21880. Int J Cancer. 2006. PMID: 16506207

8

Improvement of overall survival of patients with cutaneous melanoma in Germany, 1976-2001: which factors contributed?

Lasithiotakis KG, Leiter U, Eigentler T, Breuninger H, Metzler G, Meier F, Garbe C. Lasithiotakis KG, et al. Among authors: garbe c. Cancer. 2007 Mar 15;109(6):1174-82. doi: 10.1002/cncr.22511. Cancer. 2007. PMID: 17265520 Free article.

9

The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance.

Schittek B, Psenner K, Sauer B, Meier F, Iftner T, Garbe C. Schittek B, et al. Among authors: garbe c. Int J Cancer. 2007 May 15;120(10):2110-8. doi: 10.1002/ijc.22512. Int J Cancer. 2007. PMID: 17266041

10

Age and gender are significant independent predictors of survival in primary cutaneous melanoma.

Lasithiotakis K, Leiter U, Meier F, Eigentler T, Metzler G, Moehrle M, Breuninger H, Garbe C. Lasithiotakis K, et al. Among authors: garbe c. Cancer. 2008 Apr 15;112(8):1795-804. doi: 10.1002/cncr.23359. Cancer. 2008. PMID: 18306371 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

802 results

Search Page

Filters